Flavobacterium ceti From Blood Samples of a Korean Patient With Alcoholic Liver Cirrhosis.
Ontology highlight
ABSTRACT:
SUBMITTER: Sung JY
PROVIDER: S-EPMC4390714 | biostudies-literature | 2015 May
REPOSITORIES: biostudies-literature
Publications
Flavobacterium ceti From Blood Samples of a Korean Patient With Alcoholic Liver Cirrhosis.
Sung Ji Yeon JY Kim Taek Soo TS Shin Sue S Roh Eun Youn EY Yoon Jong Hyun JH Kim Eui-Chong EC
Annals of laboratory medicine 20150401 3
Similar Datasets
Project description: Not available
| S-EPMC5011119 | biostudies-literature
Project description:Red blood cell (RBC) alloimmunization varies across human populations and ethnic groups. We evaluated the characteristics of RBC alloimmunization and compared the risk of alloimmunization in Korean patients with myelodysplastic syndrome (MDS) and liver cirrhosis (LC), two representative diseases in which chronic transfusion is required. In total, 115 MDS patients and 202 LC patients transfused with RBCs between 2013 and 2015 were retrospectively included. Twenty patients (6.3%) were newly alloimmunized (five MDS patients, 4.3%; 15 LC patients, 7.4%). The median number of RBC units transfused in alloimmunized patients was nine (interquartile range, 4-15 units). As the number of transfused RBC units increased, the cumulative risk of alloimmunization was higher in LC than in MDS patients (P=0.001). The most common alloantibody detected in patients was anti-E (45%), followed by anti-c (17%), anti-e (10%), anti-C (7%), anti-Fyb (7%), and anti-Jka (7%). The present data indicate the need for matching of extended RBC antigens (Rh, Duffy, and Kidd systems) for chronically transfused patients with MDS and LC in Korea.
| S-EPMC6240531 | biostudies-literature
Project description:Background and aimSarcopenia frequently develops in patient with liver cirrhosis (LC). Ethanol reduces muscle protein synthesis and accelerates proteolysis. However, the relationship between heavy alcohol consumption and sarcopenia remains controversial. This study aimed to investigate the characteristics and prevalence of sarcopenia among patients with alcoholic LC (ALC) in real-world clinical settings.MethodsThis cross-sectional study included 181 patients with LC. Heavy alcohol consumption was defined as >60 g/day. Sarcopenia was diagnosed according to the Japan Society of Hepatology criteria.ResultsAmong the 181 patients, 64 (35.4%) were diagnosed with ALC. Patients with ALC were younger (median, 61.5 vs 72.0 years; P < 0.001) and had a lower prevalence of sarcopenia (18.8 vs 32.5%; P = 0.048) than those with non-ALC. Conversely, the former had a higher prevalence of Child-Pugh class B/C (P = 0.015), higher total bilirubin (P = 0.017), and lower prothrombin time (P < 0.001) than the latter. The prevalence of sarcopenia increased alongside advancing age in patients with ALC (P = 0.007). Multivariate analysis identified older age (but not disease stage/liver function reserve and alcohol consumption) as an independent factor associated with sarcopenia (P = 0.002) in patients with ALC.ConclusionPatients with ALC were younger and had a lower prevalence of sarcopenia, despite advanced disease stage/impaired liver function reserve, compared to those with non-ALC in real-world clinical settings. However, older age was strongly associated with sarcopenia, even in patients with ALC. There was no significant influence of heavy alcohol consumption on the development of sarcopenia.
| S-EPMC8264247 | biostudies-literature
Project description:Alcoholism is associated with significant changes in gut microbiota composition. Metagenomic sequencing allows to assess the altered abundance levels of bacterial taxa and genes in a culture-independent way. We collected 99 stool samples from the patients with alcoholic dependence syndrome (n=72) and alcoholic liver cirrhosis (n=27). Each of the samples was surveyed using "shotgun" (whole-genome) sequencing on SOLiD platform. The reads are deposited in the ENA (project ID: PRJEB18041).
| S-EPMC5257029 | biostudies-literature
Project description:Vibrio vulnificus is a Gram-negative bacterium, a member of the Vibrionaceae family. V. vulnificus is the main cause of seafood-related deaths in the United States because it can cause severe wound infections or sepsis. This microorganism is highly dependent on iron availability. Therefore, patients with high body iron levels are more susceptible to the infection. Prompt treatment with cephalosporins as well as doxycycline is usually administered. We present a case of V. vulnificus bacteremia in a patient heterozygous for HFE p.C282Y mutation and underlying alcoholic liver cirrhosis.
| S-EPMC10186571 | biostudies-literature
Project description:BackgroundThis study investigated the prevalence and causal relationships of chronic metabolic diseases (diabetes, hypertension, and dyslipidemia) with steatotic liver disease (SLD), specifically metabolically associated alcoholic liver disease (MetALD).MethodsWe conducted a comprehensive analysis using cross-sectional data from the KNHANES from 2011 to 2021 and the NHANES from 1999 to 2020. Longitudinal data from 2001 to 2014 from the KoGES were used. Participants were categorized into the metabolic dysfunction-associated SLD(MASLD), MetALD, and ALD groups based on their hepatic steatosis index (HSI), including liver profiles, body composition, and diabetes, and alcohol consumption. Multivariable, including age and smoking status, logistic and Cox regression analyses were performed to assess the prevalence and incidence of chronic diseases.ResultsIn both the KNHANES and NHANES cohorts, an increased HSI was significantly associated with a higher prevalence of chronic metabolic diseases. Longitudinal data from the KoGES cohort showed that MASLD and MetALD were significant predictors of chronic metabolic disease in both men and women. MetALD showed a higher hazard ratio for the development of chronic metabolic diseases than MASLD in Cox regression analysis.ConclusionsThis study highlighted the intertwined nature of SLD and metabolic health, with an emphasis on the role of MetALD. The significant association between MetALD and chronic metabolic diseases underscores the need for integrated management strategies that address both liver health and metabolic risk factors.
| S-EPMC11853905 | biostudies-literature
Project description:Alcoholic liver disease (ALD) progresses from steatosis to alcoholic hepatitis to fibrosis and cirrhosis. Liver biopsy is considered as the gold standard method for diagnosis of liver cirrhosis and provides useful information about damaging process which is an invasive procedure with complications. Existing biomarkers in clinical practice have narrow applicability due to lack of specificity and lack of sensitivity. The objective of this article is to identify proteomic biomarker candidates for alcoholic liver cirrhosis by differential expression analysis between alcoholic liver cirrhotic and healthy subjects. Blood samples were collected from 20 subjects (10 alcoholic liver cirrhosis and 10 healthy) from R. L. Jalapa Hospital and Research Centre, Kolar, Karnataka, India. Differential protein analysis was carried out by two-dimensional electrophoresis after albumin depletion, followed by liquid chromatography-mass spectrometry. The image analysis found 46 spots in cirrhotic gel and 69 spots in healthy gel, of which 14 spots were identified with significant altered expression levels. Based on the protein score and clinical significance, among 14 spots, a total of 28 protein biomarker candidates were identified: 13 with increased expression and 15 with decreased expression were categorized in alcoholic liver cirrhosis compared to healthy subjects. Protein biomarker candidates identified by "-omics" approach based on differential expression between alcoholic liver cirrhotic subjects and healthy subjects may give better insights for diagnosis of ALD. Prioritization of candidates identified is a prerequisite for validation regimen. Biomarker candidates require verification that demonstrates the differential expression will remain detectable by assay to be used for validation.
| S-EPMC6050617 | biostudies-other
Project description:The alcohol dehydrogenase 2 (ADH2) gene has been implicated in the development of alcoholic liver cirrhosis (ALC). However, the results are inconsistent. In this study, a meta-analysis was performed to assess the associations between the ADH2 polymorphism and the risk of ALC. Relevant studies were retrieved by searching PubMed, Web of Science, CNKI, Wanfang and VIP databases up to January 10, 2015. The pooled odds ratio (OR) with a 95% confidence interval (CI) was calculated using the fixed- or random effects model. A total of 21 case-control studies included 1812 cases and 3468 controls were included. Overall, the ADH2 polymorphism was associated with a decreased risk of ALC in all four genetic models (dominant model: OR=0.56, 95% CI: 0.38-0.83; recessive model: OR=0.59, 95% CI: 0.39-0.91; *1/*2 vs. *1/*1: OR=0.58, 95% CI: 0.40-0.85; *2/*2 vs *1/*1: OR=0.35, 95% CI: 0.16-0.75). Besides, in stratification analysis by ethnicity, similar results were observed in Asian populations, however, we detected no association in Caucasian populations under recessive and homozygote comparison model. The pooled evidence suggests that ADH2 polymorphism may be an important protective factor for alcoholic liver cirrhosis, especially for Asians.
| S-EPMC4509275 | biostudies-literature
Project description:This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions.
| S-EPMC8514420 | biostudies-literature
Project description:Genome-wide DNA methylation profiling of cirrhosis and dysplastic liver samples. The Illumina Infinium 450k Human DNA methylation BeadChip was used to obtain DNA methylation profiles across approximately 485,577 CpGs sites. Samples included 130 cirrhosis and 8 exhibiting dysplasia. The manuscript includes an integrative analysis of these samples along with samples from normal liver and HCC already deposited under GSE63898.
2021-06-02 | GSE157973 | GEO